Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease
BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a critical global health burden, driven by rising prevalence rates and earlier disease onset. Current therapeutic strategies remain limited to lifestyle interventions, with no approved pharmacotherapies targeti...
Saved in:
| Main Authors: | Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1600439/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
by: Huaying Wu, et al.
Published: (2025-12-01) -
Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver
by: Merve Cebi, et al.
Published: (2025-05-01) -
Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
by: Rachmad Anres Dongoran, et al.
Published: (2023-01-01) -
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value
by: Luyu Wang, et al.
Published: (2025-07-01) -
Noninvasive biomarkers implicated in urea and TCA cycles for metabolic liver disease
by: Guiyan Yang, et al.
Published: (2024-11-01)